CONFIDENCE (2025) — Trial Summary

CONFIDENCE (2025): The CONFIDENCE phase 2 trial evaluated simultaneous initiation of finerenone (nonsteroidal MRA) plus empagliflozin (SGLT2 inhibitor) versus either agent alone in patients with CKD and type 2 diabetes, testing the combination approach to kidney protection.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.